Abstract 155P
Background
Breast cancer is a public health issue both in the world and in Mexico, where 70% of patients with the disease are diagnosed in later stages. Because of this, at Instituto Nacional de Cancerología (The National Cancer Institute), neoadjuvant chemotherapy has become the standard for managing locally advanced breast cancer. However, studies show that less than 50% of patients present a complete pathologic response to this regime, which is why is essential to identify molecular biomarkers capable of predicting resistance to this therapy. Thus, the use of machine learning techniques, together with transcriptome analyses could contribute to the management of oncological treatments for this stage of the disease.
Methods
We included 118 samples corresponding to patients classified in the Luminal A, Luminal B, HER2, and Triple Negative subtypes in locally advanced stages who did not present metastasis or had not received treatment at the time of biopsy in the period 2012 - 2015. RNA was extracted from fresh tumor biopsies prior to the administration of neoadjuvant chemotherapy. After obtaining the results of the clinical monitoring of response to the treatment, the patient samples were grouped as "control" if they presented complete pathological response to the treatment, and "case" if they presented resistance. Subsequently, the total RNA of the samples was processed by massive RNA sequencing (RNA-seq) and a differential expression analysis was performed using DESeq2. Finally, machine learning algorithms were used to select a group of genes capable of classifying patients into "resistant" and "non-resistant" and a panel of response biomarkers was proposed.
Results
A set of mRNAs and lncRNAs capable of discriminating the outcome of breast cancer patients to neoadjuvant chemotherapy as well as the enriched pathways associsted with them was identified.
Conclusions
We propose a preliminary biomarker panel, wich will later be tested and validated in large, well-designed, prospective clinical trials. The validation of molecular biomarkers and their eventual incorporation into clinical practice will improve personalized cancer treatments and the management of advanced stages.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
Instituto Nacional de Cancerología INCan (018/055/DII) (CEI/1302/18).
Funding
Instituto Nacional de Cancerología INCan (018/055/DII) (CEI/1302/18).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
103P - MSI detection by NGS using tumor samples and liquid biopsy for patients with solid tumors: A single institution experience
Presenter: Alexandra Lebedeva
Session: Cocktail & Poster Display session
Resources:
Abstract
104P - Hypomethylated immune gene promoters as potential biomarkers in oral and oropharyngeal cancer
Presenter: Petra Anić
Session: Cocktail & Poster Display session
Resources:
Abstract
105P - Implementation of technical improvements in cfMeDIP-Seq library preparation
Presenter: Martina Dameri
Session: Cocktail & Poster Display session
Resources:
Abstract
106P - Clinical application of next-generation sequencing in metastatic colorectal cancer (mCRC): Experience from a comprehensive cancer centre
Presenter: David Lluís Garulo
Session: Cocktail & Poster Display session
Resources:
Abstract
107P - Unveiling mismatch repair deficiency (dMMR) and microsatellite-instability high (MSI-H) detection in cancer patients (pt) using a next-generation sequencing (NGS)-based molecular pre-screening program (MPP)
Presenter: Lucia Notario Rincon
Session: Cocktail & Poster Display session
Resources:
Abstract
108P - Validation and implementation of a large NGS panel to test liquid biopsies from patients with suspected advanced non-small cell lung cancer (NSCLC) in an NHS genomic laboratory for the QuicDNA biomarker study
Presenter: Rachel Dodds
Session: Cocktail & Poster Display session
Resources:
Abstract
109P - A multiomic, single-cell measurable residual disease (scMRD) assay for phasing DNA mutations and surface immunophenotypes
Presenter: Simone Formisano
Session: Cocktail & Poster Display session
Resources:
Abstract
110P - Multicellular three-dimensional tumor spheroid of nasopharyngeal carcinoma
Presenter: Shiau Chuen Cheah
Session: Cocktail & Poster Display session
Resources:
Abstract
111P - Development of digital PCR for accurate measurement of HER2 amplification in 184 gastric cancer patients
Presenter: So Young Kang
Session: Cocktail & Poster Display session
Resources:
Abstract
112P - A novel methylation-sensitive assay for early detection of hepatocellular carcinoma to improve surveillance
Presenter: Jeong Sil Ha
Session: Cocktail & Poster Display session
Resources:
Abstract